TScan Therapeutics (TCRX) Other Non Operating Income (2022 - 2026)

TScan Therapeutics (TCRX) has reported Other Non Operating Income for 5 consecutive years, with $473000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non Operating Income fell 77.72% year-over-year to $473000.0; the TTM figure through Mar 2026 stood at $4.4 million (down 46.47% YoY), while the FY2025 annual figure was $6.0 million, down 17.41% from the prior year.
• Other Non Operating Income retreated to $473000.0 in Q1 2026 per TCRX's latest filing, from $881000.0 in the prior quarter.
• Across five years, Other Non Operating Income topped out at $2.7 million in Q3 2024 and bottomed at -$74000.0 in Q4 2022.
• Historically, Other Non Operating Income has averaged $1.1 million across 5 years, with a median of $903000.0 in 2024.
• Annual changes were most pronounced in 2023 — Other Non Operating Income surged 2471.43% — and 2026, when it plunged 77.72%.
• TScan Therapeutics' Other Non Operating Income stood at -$74000.0 in 2022, then surged by 2456.76% to $1.7 million in 2023, then tumbled by 48.22% to $903000.0 in 2024, then declined by 2.44% to $881000.0 in 2025, then sank by 46.31% to $473000.0 in 2026.
• Business Quant data shows TCRX's Other Non Operating Income at $473000.0 in Q1 2026, $881000.0 in Q4 2025, and $1.3 million in Q3 2025.